Oesophageal Cancer Trial, Recruiting (NCT03222895)

Oesophageal Cancer Trial, Recruiting NCT03222895 Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Condition: Oesophageal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT03222895 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Oesophageal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with a specific type of esophageal cancer (squamous cell or adenocarcinoma) located in the esophagus or where the esophagus meets the stomach.
People whose cancer has been assessed as removable by surgery, based on standard staging categories (confirm with trial site).
People who are in a physical condition suitable for major chest surgery, as assessed by their medical team.
People who are planned to undergo a specific type of esophageal surgery that goes through the chest (transthoracic esophagectomy).

Who may not be able to join:

People who have previously had surgery on the chest or upper abdomen that may have affected how fluid drains from the esophagus or stomach.
People whose condition has been diagnosed as early-stage cancer that has not yet spread into surrounding tissue (in situ carcinoma) or a pre-cancerous condition called high grade dysplasia.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Suzanne S Gisbertz, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phone: +31205669111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03222895

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase: Not Applicable

Status: Recruiting

Condition: Oesophageal Cancer

Trial contact: +31205669111

More information: https://clinicaltrials.gov/study/NCT03222895

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with a specific type of esophageal cancer (squamous cell or adenocarcinoma) located in the esophagus or where the esophagus meets the stomach.
People whose cancer has been assessed as removable by surgery, based on standard staging categories (confirm with trial site).
People who are in a physical condition suitable for major chest surgery, as assessed by their medical team.
People who are planned to undergo a specific type of esophageal surgery that goes through the chest (transthoracic esophagectomy).

Who may not be able to join:

People who have previously had surgery on the chest or upper abdomen that may have affected how fluid drains from the esophagus or stomach.
People whose condition has been diagnosed as early-stage cancer that has not yet spread into surrounding tissue (in situ carcinoma) or a pre-cancerous condition called high grade dysplasia.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Registry

ClinicalTrials.gov

Start date

1 March 2019

Est. completion

1 January 2025

Where this trial is recruiting

🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇫🇮 Finland 🇩🇪 Germany 🇬🇷 Greece Hong Kong 🇮🇳 India 🇮🇹 Italy 🇯🇵 Japan 🇳🇱 Netherlands 🇪🇸 Spain 🇸🇪 Sweden 🇺🇸 United States

Primary endpoints

Distribution of lymph node metastases

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov